Evonik Invests $100m in Tippecanoe Drug Substance Site

Evonik has committed $100 million over the next five years to modernise its Lafayette (Tippecanoe), Indiana drug substance CDMO facility, one of the world’s largest active pharmaceutical ingredient (API) manufacturing sites. Announced on 14 July 2026 and supported by local government, the investment upgrades reactors and other critical equipment to meet accelerating demand for US-based drug substance contract manufacturing at a moment when geopolitical uncertainty is reshaping pharma supply strategy.

The Tippecanoe site is Evonik’s second-largest US location and one of the industry’s largest API facilities. It houses the sector’s largest high-potency API (HPAPI) operation at 170 m3 dedicated capacity with containment down to 0.1 μg/m3, 860 m3 of general API reactor capacity, 2,500 m3 for large-scale fermentation and ten advanced technology platforms. The $100 million investment upgrades key equipment including 100 m3 reactors, expanding automation and improving energy efficiency. Evonik acquired the site from Eli Lilly in 2010 and has since developed it into a multi-customer CDMO for complex drug substance projects.

Guido Skudlarek, head of Health Care business line at Evonik, framed strengthening the US drug substance business as a strategic necessity given surging demand and the need for a globally balanced asset footprint. Evonik is balancing capacity across North America, Europe and Asia, with strategic emphasis on North America for its Drug Substance CDMO business, as geopolitical uncertainties highlight the importance of Western-based production. Daniel Fricker, Head of the Drug Substance Product Line, noted that rising API complexity in cancer, metabolic and cardiovascular disease programmes is now a defining driver of CDMO investment strategy.

The commercial signal is a substantial acceleration in the US pharma reshoring narrative, sitting alongside recent J&J Jacksonville, Thermo Fisher Plainville and Danaher moves. With API complexity rising and geopolitical uncertainty pushing branded pharma toward Western-based supply, expect continued CDMO capex commitments through the remainder of 2026. Evonik’s HPAPI positioning gives it particular leverage in oncology and metabolic disease franchises.

For the latest updates and in-depth insights into the world of Life Science, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!